Sucampo Pharmaceuticals Inc. to Post FY2016 Earnings of $1.21 Per Share, Leerink Swann Forecasts (SCMP)
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) – Stock analysts at Leerink Swann upped their FY2016 earnings per share (EPS) estimates for Sucampo Pharmaceuticals in a research note issued to investors on Wednesday. Leerink Swann analyst J. Gerberry now anticipates that the brokerage will post earnings per share of $1.21 for the year, up from their previous estimate of $1.03. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ Q1 2017 earnings at $0.32 EPS, Q2 2017 earnings at $0.38 EPS, Q3 2017 earnings at $0.46 EPS, Q4 2017 earnings at $0.56 EPS, FY2019 earnings at $1.87 EPS and FY2020 earnings at $2.16 EPS.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.26 by $0.02. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 48.57%. The company had revenue of $57.90 million for the quarter, compared to analyst estimates of $51.30 million. During the same quarter last year, the business earned $0.16 earnings per share. Sucampo Pharmaceuticals’s revenue was up 73.4% compared to the same quarter last year.
Several other analysts have also issued reports on SCMP. Jefferies Group restated a “hold” rating and issued a $16.00 price target (up from $14.00) on shares of Sucampo Pharmaceuticals in a research report on Friday. Vetr upgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $14.00 price target on the stock in a research report on Thursday, September 29th. Maxim Group decreased their target price on shares of Sucampo Pharmaceuticals from $26.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, August 1st. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. Finally, Mizuho lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $13.00 target price on the stock. in a research report on Thursday, August 4th. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Sucampo Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $16.78.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 15.20 on Friday. The firm has a market cap of $645.98 million, a price-to-earnings ratio of 20.82 and a beta of 1.62. The firm has a 50 day moving average of $12.64 and a 200 day moving average of $11.75. Sucampo Pharmaceuticals has a 52 week low of $9.59 and a 52 week high of $18.75.
Several institutional investors have recently made changes to their positions in SCMP. Zacks Investment Management bought a new position in shares of Sucampo Pharmaceuticals during the second quarter worth $110,000. Boothbay Fund Management LLC bought a new position in shares of Sucampo Pharmaceuticals during the first quarter worth $114,000. Smith Asset Management Group LP increased its position in shares of Sucampo Pharmaceuticals by 69.5% in the second quarter. Smith Asset Management Group LP now owns 10,730 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 4,400 shares in the last quarter. Princeton Alpha Management LP bought a new position in shares of Sucampo Pharmaceuticals during the second quarter worth $138,000. Finally, Nine Chapters Capital Management LLC bought a new position in shares of Sucampo Pharmaceuticals during the third quarter worth $142,000. 38.91% of the stock is owned by institutional investors.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.